Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Paclitaxel for injection (albumin-bound)
Drug: Adebrelimab
Drug: Apatinib mesylate

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-29

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 30

Registration Number: NCT06415669

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Fuzhou, Fujian, China

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma
Adebrelimab

Interventions: Drug: Adebrelimab

First Posted Date: 2024-05-08

Last Posted Date: 2024-07-15

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 40

Registration Number: NCT06405061

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
🇨🇳
Third Central Hospital of Tianjin, Tianjin, Tianjin, China

and more 1 locations

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Phase 2

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Adebrelimab
Drug: Lenvatinib
Procedure: Hepatic Arterial Infusion Chemotherapy

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Harbin Medical University

Target Recruit Count: 30

Registration Number: NCT06389500

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: RC48
Drug: Adebrelimab
Drug: Apatinib
Drug: S-1

First Posted Date: 2024-04-26

Last Posted Date: 2024-05-13

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 32

Registration Number: NCT06385873

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1

Conditions: Advanced KRAS G12D Mutant Solid Tumors

Interventions: Drug: HRS-4642
Drug: Adebrelimab
Drug: Cetuximab Solution for Infusion
Drug: SHR-9839
Drug: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection

First Posted Date: 2024-04-26

Last Posted Date: 2025-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 70

Registration Number: NCT06385678

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Phase 2

Not yet recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Adebrelimab

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06375642

Locations: 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Phase 1

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: SHR-8068
Drug: Adebrelimab
Drug: BP102

First Posted Date: 2024-04-18

Last Posted Date: 2024-04-18

Lead Sponsor: West China Hospital

Target Recruit Count: 36

Registration Number: NCT06373133

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Phase 2

Recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Adebrelimab plus Apatinib
Drug: Adebrelimab plus Bevacizumab
Drug: Camrelizumab plus Apatinib

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-22

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 111

Registration Number: NCT06360042

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Cldn18.2-positive Advanced Solid Tumor

Interventions: Drug: SHR-A1904; Adebrelimab
Drug: SHR-A1904; CAPOX; Adebrelimab

First Posted Date: 2024-04-05

Last Posted Date: 2024-08-09

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 924

Registration Number: NCT06350006

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Adebrelimab and Chemoradiotherapy in High-risk LANPC

Phase 2

Recruiting

Conditions: Nasopharyngeal Cancer
Nasopharyngeal Carcinoma

Interventions: Drug: Adebrelimab

First Posted Date: 2024-04-05

Last Posted Date: 2025-01-15

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT06349889

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy